Utility of Risk Stratification for Paclitaxel Hypersensitivity Reactions
- 1 July 2018
- journal article
- research article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 6 (4) , 1266-1273.e2
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergyAnnals of Allergy, Asthma & Immunology, 2015
- Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitizationAllergy, 2015
- Management of Hypersensitivity Reactions to Carboplatin and Paclitaxel in an Outpatient Oncology Infusion Center: A 5-Year ReviewThe Journal of Allergy and Clinical Immunology: In Practice, 2014
- Oxaliplatin Hypersensitivity: Evaluation, Implications of Skin Testing, and DesensitizationThe Journal of Allergy and Clinical Immunology: In Practice, 2014
- A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactionsJournal of Allergy and Clinical Immunology, 2012
- A fatal anaphylactic reaction to paclitaxel is described, which was preceded by a possible delayed reaction to the initial infusionAllergy and Asthma Proceedings, 2011
- Risk stratification for desensitization of patients with carboplatin hypersensitivity: Clinical presentation and managementJournal of Allergy and Clinical Immunology, 2009
- Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 casesJournal of Allergy and Clinical Immunology, 2008
- Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatmentsGynecologic Oncology, 2005
- Taxol1 (Paclitaxel) in Patients with Metastatic Breast Carcinoma Who Have Failed Prior Chemotherapy: Interim Results of a Multinational StudyOncology, 1994